Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

More Biosimilars Marketed in Germany, Switzerland Than U.S.

admin by admin
December 4, 2022
in News


FRIDAY, Dec. 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.

David L. Carl, from the University of Zurich, and colleagues examined uptake and prices of biosimilars in the United States versus Germany and Switzerland in a cohort study. For 2011 to 2020, prices and sales data were extracted from public and commercial databases.

The study cohort included 15 biosimilars and six biologics for the United States; 52 and 15 for Germany; and 28 and 13 for Switzerland. The researchers found that in all countries, uptake of biosimilars increased over time. On average, the highest biosimilar market share at launch was seen in Germany; however, in the United States, it increased at the fastest rate. Monthly treatment costs of biosimilars were a median of 1.94 and 2.74 higher in the United States versus the corresponding costs in Germany and Switzerland.

“Policies for drug pricing negotiations in the United States against anticompetitive practices of exclusionary contracts could allow biosimilars to enter the market sooner and at lower costs, which could result in lower health care costs and improved patient access,” the authors write. “Awareness of biosimilars should be promoted to increase the uptake of biosimilars in all three countries.”

Abstract/Full Text

Copyright © 2022 HealthDay. All rights reserved.
healthday



Source link

Advertisement Banner
Previous Post

Airway Management of Patients in Hospice and Palliative Care

Next Post

‘Breaking Down Interstate Barriers to Telehealth Delivery’ Tops ATA’s Priorities for 2023 – The Health Care Blog

Related Posts

News

Novel Non-Antibody Fusion Protein Effective for Sjögren’s Syndrome

June 7, 2023
News

Examining the Role of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With CD

June 6, 2023
News

Understanding the Progression of Very Early-Onset Inflammatory Bowel Disease: A Clinical Perspective

June 5, 2023
News

ASCO: Phone-Based Coaching Helps Breast Cancer Patients Lose Weight

June 4, 2023
News

Double Dissociation of Orientation & Brightness Judgments: Investigating Visual Crowding Effects

June 3, 2023
News

Strategies for Enhancing Workforce Representation

June 2, 2023
Next Post

‘Breaking Down Interstate Barriers to Telehealth Delivery’ Tops ATA’s Priorities for 2023 – The Health Care Blog

Recommended

Tilsotolimod Boosts Antigen Presentation and Type 1 IFN in Solid Tumors

5 months ago

Pegylated interferon lambda reduces the risk of COVID-19-related hospitalization

4 months ago

Expanding Real World Datasets – The Health Care Blog

5 months ago

Cut: A Surgery Movie

1 month ago

Journalism fellowships to help support environmental health coverage

2 weeks ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.